Well, at least that's true when we are blogging about
defense wins. And this week, we have another good gadolinium case.
This time from New York.
Just a quick reminder – gadolinium is a contrast agent
that is injected into a patient before undergoing an MRI. The
gadolinium is intended to pass through the body, but there are
known risks of retention in patients with impaired kidney
function.
Plaintiff in Sabol v. Bayer Healthcare Pharm, Inc.,
2020 WL 705170, *1 (S.D.N.Y. Feb. 12, 2020) underwent a remarkable
23 MRIs between 2007 and 2015, and each time she was injected with
a gadolinium contrast agent. As in our other recent gadolinium
posts, plaintiff here had normal kidney function. Her lawsuit,
therefore, hinges on her contention that defendants should have
warned of the risks of gadolinium retention in patients with normal
kidney function.
